Alonso Alvaro, Jick Susan S, Hernán Miguel A
Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA.
Neurology. 2006 Feb 28;66(4):572-5. doi: 10.1212/01.wnl.0000198507.13597.45.
It is unclear whether allergic diseases are associated with multiple sclerosis (MS), but histamine 1 receptor blockers, used in the treatment of allergic conditions, decreased the severity of experimental autoimmune encephalomyelitis (an animal model of MS).
To assess the association of allergy history and use of histamine 1 receptor blockers with the risk of MS.
Using a case-control study nested in the United Kingdom-based General Practice Research Database cohort, the authors identified 163 incident cases of MS with at least 3 years of follow-up before their first symptoms (index date). Up to 10 controls matched to the cases by age, sex, general practice, and time in the cohort were selected. Previous history of allergic disease and use of histamine 1 receptor blockers in the 3 years before the index date were assessed through computerized medical records.
History of any allergic condition in the 3 years before the index date was not associated with MS risk (adjusted odds ratio [OR] 1.2, 95% CI 0.8 to 1.8). However, use of sedating histamine 1 receptor blockers was associated with decreased MS risk (adjusted OR 0.2, 95% CI 0.1 to 0.8).
These results do not support a strong link between allergic conditions and multiple sclerosis (MS) risk but suggest a possible beneficial effect of antihistamines on the onset of MS.
过敏性疾病与多发性硬化症(MS)之间是否存在关联尚不清楚,但用于治疗过敏症的组胺1受体阻滞剂可降低实验性自身免疫性脑脊髓炎(MS的一种动物模型)的严重程度。
评估过敏史和组胺1受体阻滞剂的使用与MS风险之间的关联。
作者利用嵌套于英国全科医学研究数据库队列中的病例对照研究,确定了163例MS发病病例,这些病例在首次出现症状(索引日期)前至少有3年的随访时间。选择年龄、性别、全科医疗情况和队列中的时间与病例匹配的多达10名对照。通过计算机化医疗记录评估索引日期前3年的过敏疾病既往史和组胺1受体阻滞剂的使用情况。
索引日期前3年的任何过敏情况病史与MS风险无关(调整后的优势比[OR]为1.2,95%可信区间为0.8至1.8)。然而,使用镇静性组胺1受体阻滞剂与MS风险降低有关(调整后的OR为0.2,95%可信区间为0.1至0.8)。
这些结果不支持过敏情况与多发性硬化症(MS)风险之间存在紧密联系,但提示抗组胺药对MS发病可能具有有益作用。